News Results

There are 121,850 News Results

Nov 20, 2017
Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
RARITAN, N.J., Nov. 21, 2017 /PRNewswire/ -- Janssen Biotech, Inc. today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA)...
Nov 29, 2017
FDA Approves SUBLOCADE(TM) (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder
RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE(TM) (buprenorphine extended- release)...
Dec 8, 2017
Bioengineering and Specialized Therapies Yield Results for Rare and Challenging Blood Diseases
ATLANTA, Dec. 9, 2017 /PRNewswire-USNewswire/ -- In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings...
Dec 9, 2017
Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies
ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ -- Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in...
Dec 9, 2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
EAST HANOVER, N.J., Dec. 10, 2017 /PRNewswire/ -- Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah(TM) (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019,...
Dec 10, 2017
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
ATLANTA and RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous...
Dec 11, 2017
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
ATLANTA, Dec. 12, 2017 /PRNewswire-USNewswire/ -- In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising...
Dec 11, 2017
DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
ATLANTA and RARITAN, N.J., Dec. 12, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX(®) (daratumumab) in combination with...
Dec 19, 2017
Blockchain-Powered Cryptocurrency Revolution Boosts Early Adopters
NEW YORK, December 20, 2017 /PRNewswire/ -- The astounding surge in the price of cryptocurrencies in 2017, most notably bitcoin's rise from around $1,000 at the start of the year...
Jan 9, 2018
CES 2018 I Cision Roundup
NEW YORK, Jan. 10, 2018 /PRNewswire/ -- The following roundup is a collection of stories dealing with the 2018 CES Tradeshow and is appropriate for special sections and for general...
12185

Pages

1

Stories of the day

Jul 30, 2025
Rheinmetall expands local production in Romania and strengthens the Romanian...
Jul 30, 2025
Moog’s Genesys Avionics Suite Selected for T-6A Avionics Program
Jul 30, 2025
RTXs Raytheon introduces advanced targeting system for U.S. Navy helicopters
Jul 30, 2025
Lockheed Martin Delivers 250th MK 48 Guidance and Control Section